All In Biotech

Drug Trial Radar · NCT04383262

Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction

A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Oral Fosamprenavir for Laryngopharyngeal Reflux

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Jul 1, 2027

Study completion Oct 1, 2028

Sponsor

Lead sponsor
Medical College of WisconsinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Laryngopharyngeal Reflux (LPR) is a common condition that causes symptoms like chronic cough, throat clearing, hoarseness, and trouble swallowing. If not treated, LPR can lead to long-term throat damage and may increase the risk of throat cancer. More than 20% of the people in the United States are estimated to have LPR, yet there is no effective medication approved to treat it. Drugs called proton pump inhibitors (PPIs) are often used to treat LPR, even though they were designed for stomach acid problems. These medications reduce acid but do not stop reflux from happening, so they often do not help LPR patients. Despite poor results, PPIs are widely prescribed, are very costly, and can cause side effects. Research shows that a digestive enzyme called pepsin plays a key role in LPR. Pepsin can damage the throat and voice box even when acid is not present. Laboratory studies found that certain HIV medications can block damage caused by pepsin. People taking these medications for HIV appear to have a much lower rate of LPR. This study will test fosamprenavir, an FDA-approved HIV drug, as a treatment for LPR. We will conduct a 14-week, double-blind, placebo-controlled clinical trial in patients with LPR who did not improve with standard treatment. Participants will receive either fosamprenavir or placebo, randomly, and symptoms will be measured before and after treatment using standard questionnaires and daily symptom tracking. Because there is no effective medical treatment for LPR. this study aims to test a safe, existing drug that targets the underlying cause of the disease.

Conditions

  • Laryngopharyngeal Reflux

Interventions

  • Fosamprenavir CalciumDrug

    A repurposing approach, prospective, placebo-controlled clinical trial of Fosamprenavir (used at 1,400 mg fosamprenavir calcium, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI \> 13, RFS \> 7 and MII-pH confirmed laryngeal reflux event\[s\]).

  • PlaceboOther

    Non-active placebo pill formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Reflux Symptom Index (RSI)Time frame: Baseline to 12-week post-treatment.
  2. Change in Daily Symptom Reflux Diary (DRSD)Time frame: Baseline to 12-week post-treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Froedtert Hospital

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.